CA2901613A1 - Inhibiteurs doubles de mek/pi3k et procedes therapeutiques les utilisant - Google Patents

Inhibiteurs doubles de mek/pi3k et procedes therapeutiques les utilisant

Info

Publication number
CA2901613A1
CA2901613A1 CA2901613A CA2901613A CA2901613A1 CA 2901613 A1 CA2901613 A1 CA 2901613A1 CA 2901613 A CA2901613 A CA 2901613A CA 2901613 A CA2901613 A CA 2901613A CA 2901613 A1 CA2901613 A1 CA 2901613A1
Authority
CA
Canada
Prior art keywords
compound
6alkyl
independently
hydrogen
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2901613A
Other languages
English (en)
Other versions
CA2901613C (fr
Inventor
Brian D. Ross
Marcian VAN DORT
Christopher Whitehead
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan
Original Assignee
University of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan filed Critical University of Michigan
Publication of CA2901613A1 publication Critical patent/CA2901613A1/fr
Application granted granted Critical
Publication of CA2901613C publication Critical patent/CA2901613C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des inhibiteurs doubles de MEK et PI3K et des compositions contenant les mêmes. L'invention concerne aussi des procédés d'utilisation des inhibiteurs doubles de MEK/PI3K dans le traitement de maladies et de troubles, comme les cancers, où l'inhibition de MEK et PI3K fournit un bénéfice.
CA2901613A 2013-03-13 2014-03-12 Inhibiteurs doubles de mek/pi3k et procedes therapeutiques les utilisant Active CA2901613C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361779462P 2013-03-13 2013-03-13
US61/779,462 2013-03-13
PCT/US2014/023860 WO2014164942A1 (fr) 2013-03-13 2014-03-12 Inhibiteurs doubles de mek/pi3k et procédés thérapeutiques les utilisant

Publications (2)

Publication Number Publication Date
CA2901613A1 true CA2901613A1 (fr) 2014-10-09
CA2901613C CA2901613C (fr) 2020-10-20

Family

ID=51659015

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2901613A Active CA2901613C (fr) 2013-03-13 2014-03-12 Inhibiteurs doubles de mek/pi3k et procedes therapeutiques les utilisant

Country Status (6)

Country Link
US (1) US9611258B2 (fr)
EP (1) EP2968345B1 (fr)
JP (1) JP6315848B2 (fr)
CN (1) CN105358156A (fr)
CA (1) CA2901613C (fr)
WO (1) WO2014164942A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2785551T3 (es) 2014-06-30 2020-10-07 Glykos Finland Oy Derivado de sacárido de una carga útil tóxica y sus conjugados con anticuerpos
US9968604B2 (en) 2015-04-16 2018-05-15 Chiesi Farmaceutici S.P.A. Chromene derivatives as phoshoinositide 3-kinases inhibitors
CA3004530A1 (fr) 2015-11-07 2017-05-11 Multivir Inc. Methodes et compositions comprenant une therapie genique suppressive de tumeur et le blocage du point de controle immunitaire pour le traitement du cancer
CN109563088B (zh) * 2016-07-06 2022-10-11 密歇根大学董事会 MEK/PI3K和mTOR/MEK/PI3K的多功能抑制剂和治疗用途
EP3551226A1 (fr) 2016-12-12 2019-10-16 MultiVir Inc. Méthodes et compositions comprenant une thérapie génique virale et un inhibiteur de point de contrôle immunitaire pour le traitement et la prévention du cancer et des maladies infectieuses
AU2018316175B2 (en) * 2017-08-11 2023-02-23 The Regents Of The University Of Michigan Inhibitors of MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR and MEK/PI3K3k/mTOR biological pathways and methods for improving lymphatic uptake, bioavailability, and solubility of therapeutic compounds
KR20200135986A (ko) 2018-03-19 2020-12-04 멀티비르 인코포레이티드 종양 억제인자 유전자 치료 및 cd122/cd132 작용제를 포함하는 암 치료를 위한 방법 및 조성물
WO2021113644A1 (fr) 2019-12-05 2021-06-10 Multivir Inc. Combinaisons comprenant un activateur de lymphocytes t cd8+, un inhibiteur de point de contrôle immunitaire et une radiothérapie en vue d'obtenir des effets ciblés et abscopal pour le traitement du cancer
US20230119327A1 (en) * 2020-01-10 2023-04-20 Immuneering Corporation Mek inhibitors and therapeutic uses thereof
CN111135309B (zh) * 2020-01-15 2023-04-28 重庆大学 一种核壳结构的替拉扎明药物载体及其制备方法和应用
AR121078A1 (es) 2020-01-22 2022-04-13 Chugai Pharmaceutical Co Ltd Derivados de arilamida con actividad antitumoral
WO2023133472A1 (fr) * 2022-01-06 2023-07-13 Immuneering Corporation Inhibiteurs oncologiques immunitaires de mek et leurs utilisations thérapeutiques

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960614B2 (en) * 2000-07-19 2005-11-01 Warner-Lambert Company Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids
AR059339A1 (es) 2006-02-09 2008-03-26 Chugai Pharmaceutical Co Ltd Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene
WO2008032033A1 (fr) * 2006-09-14 2008-03-20 Astrazeneca Ab Dérivés de 4-benzimidazolyl-2-morpholino-6-pipérazinylpyrimidine utilisés en tant que pi3k et inhibiteurs de mtor destinés au traitement de troubles prolifératifs
WO2008032060A1 (fr) * 2006-09-14 2008-03-20 Astrazeneca Ab Dérivés de 4-benzimidaz0lyl-6-m0rph0lin0-2-pipérazinylpyrimidine utilisés comme inhibiteurs de p13k et mtor dans le traitement de troubles prolifératifs
EP2172198B1 (fr) * 2007-07-20 2014-04-16 Chugai Seiyaku Kabushiki Kaisha INDUCTEUR DE PROTÉINE p27
EP2276750A2 (fr) * 2008-03-27 2011-01-26 Auckland Uniservices Limited Pyrimidines et triazines substituées, et leur utilisation en thérapie anticancéreuse
CN102089007B (zh) * 2008-07-11 2013-05-15 诺瓦提斯公司 (a)磷酸肌醇3-激酶抑制剂和(b)ras/raf/mek通路调节剂的组合产品
US8461158B2 (en) 2009-03-27 2013-06-11 Pathway Therapeutics Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
TW201105662A (en) 2009-07-07 2011-02-16 Pathway Therapeutics Ltd Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
US20110166191A1 (en) 2010-01-07 2011-07-07 Shijun Zhang 3-(2-amino-ethyl)-5-(3-cyclohexyl-propylidene)-thiazolidine-2,4-dione and its derivatives as multiple signaling pathway inhibitors and for the treatment of cancer
GB201007227D0 (en) 2010-04-30 2010-06-16 Univ Basel Piperazinotriazines
ES2791716T3 (es) * 2010-12-14 2020-11-05 Univ Maryland Células T que expresan al receptor de antígeno quimérico antietiqueta universal y métodos para el tratamiento del cáncer

Also Published As

Publication number Publication date
EP2968345A1 (fr) 2016-01-20
CA2901613C (fr) 2020-10-20
EP2968345B1 (fr) 2017-12-13
US9611258B2 (en) 2017-04-04
EP2968345A4 (fr) 2016-08-17
WO2014164942A1 (fr) 2014-10-09
CN105358156A (zh) 2016-02-24
JP6315848B2 (ja) 2018-04-25
JP2016516702A (ja) 2016-06-09
US20160002212A1 (en) 2016-01-07

Similar Documents

Publication Publication Date Title
EP2968345B1 (fr) Inhibiteurs dual de mek/pi3k et utilisation pour le traitement des maladies de cancer
EP2888265B1 (fr) Inhibiteurs bivalents de protéines iap et méthodes thérapeutiques les utilisant
EP2668180B1 (fr) Inhibiteurs de bcl-2/bcl-xl pour l'utilisation dans le traitement des maladies de cancer
AU2021202619B2 (en) Multifunctional inhibitors of MEK/PI3K and mTOR/MEK/PI3K biological pathways and therapeutic methods using the same
EP2356093B1 (fr) Composés carbazole et utilisations thérapeutiques desdits composés
US20110319362A1 (en) Stat3 ligands and therapeutic uses thereof
WO2011159685A2 (fr) Inhibition de l'interaction de la protéine wdr5 avec ses partenaires de liaison et méthodes thérapeutiques associées
MX2007000265A (es) Compuestos utiles para inhibir chk1.
EA034235B1 (ru) Новые композиции, их использование и способы получения
WO2013082017A1 (fr) Petites molécules peptido-mimétiques cyclisées inhibitrices de l'interaction entre wdr5 et mll1.
AU2022311961A1 (en) Small molecule cyclin dependent kinase 4/6 (cdk4/6) and ikzf2 (helios) degraders and methods of use thereof
CN117263944A (zh) 泛素特异性蛋白酶1抑制剂及其用途
WO2023133260A2 (fr) Régulateur de la chromatine, de la sous-famille a, élément 4 (smarca4) dépendant de l'actine, associé à la matrice, relatif à swi/snf de ciblage chimique, et son utilisation dans un gliome pontique intrinsèque diffus (dipg)
AU2015228385A1 (en) Compounds for eradicating or inhibiting proliferation of cancer stem cells

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181017